Comparative Pharmacology
Head-to-head clinical analysis: DERMATOP versus LOCOID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DERMATOP versus LOCOID.
DERMATOP vs LOCOID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Prednicarbate is a corticosteroid that induces phospholipase A2 inhibitory proteins, collectively called lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of arachidonic acid from membrane phospholipids.
Topical corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties. Binds to glucocorticoid receptors, modulating gene expression to inhibit phospholipase A2, reduce prostaglandin and leukotriene synthesis, and suppress cytokine production.
Apply a thin layer to affected skin areas twice daily (morning and evening) for up to 4 weeks. Do not use more than 50 g per week.
Topical: Apply a thin layer to affected area once or twice daily. Maximum: 30-60 g per week. Not for use >2 consecutive weeks or on >50% of body surface.
None Documented
None Documented
Terminal elimination half-life: approximately 100 hours (range 68-120 hours) following topical administration; prolonged accumulation with chronic use due to high lipophilicity and slow release from skin depot.
Terminal elimination half-life: 30-40 hours; clinically significant for once-daily dosing and prolonged action
Primarily hepatic metabolism with inactive metabolites; <10% excreted renally as unchanged drug; minimal biliary/fecal elimination.
Renal (approximately 60-70%) as conjugated metabolites; biliary/fecal (approximately 20-30%)
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid